609 Stock Overview
A biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ABIONYX Pharma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.22 |
| 52 Week High | €1.28 |
| 52 Week Low | €1.06 |
| Beta | 0.48 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -42.04% |
| 5 Year Change | 1.67% |
| Change since IPO | -57.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 609 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 2.5% |
| 1Y | n/a | -13.8% | 13.4% |
Return vs Industry: Insufficient data to determine how 609 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 609 performed against the German Market.
Price Volatility
| 609 volatility | |
|---|---|
| 609 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 609's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 609's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 61 | Cyrille Tupin | abionyx.com |
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019.
ABIONYX Pharma SA Fundamentals Summary
| 609 fundamental statistics | |
|---|---|
| Market cap | €43.62m |
| Earnings (TTM) | -€4.40m |
| Revenue (TTM) | €4.60m |
9.5x
P/S Ratio-9.9x
P/E RatioIs 609 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 609 income statement (TTM) | |
|---|---|
| Revenue | €4.60m |
| Cost of Revenue | €3.70m |
| Gross Profit | €900.00k |
| Other Expenses | €5.30m |
| Earnings | -€4.40m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 25, 2025
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 19.57% |
| Net Profit Margin | -95.65% |
| Debt/Equity Ratio | 33.6% |
How did 609 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/02 20:51 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ABIONYX Pharma SA is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fanny Meindre | CIC Market Solutions (ESN) |
| Stephanie Lefebvre | Gilbert Dupont |
| Jamila El Bougrini | Gilbert Dupont |